A Randomized, Double-Blind, Phase III Study to Evaluate Adjuvant cG250 [WX G250; Rencarex; Wilex] Treatment Versus Placebo in Patients With Clear Cell RCC [renal cell carcinoma] and High Risk of Recurrence.

Trial Profile

A Randomized, Double-Blind, Phase III Study to Evaluate Adjuvant cG250 [WX G250; Rencarex; Wilex] Treatment Versus Placebo in Patients With Clear Cell RCC [renal cell carcinoma] and High Risk of Recurrence.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 01 Feb 2014

At a glance

  • Drugs Girentuximab (Primary)
  • Indications Renal cancer
  • Focus Biomarker; Registrational; Therapeutic Use
  • Acronyms ARISER
  • Sponsors WILEX AG
  • Most Recent Events

    • 01 Feb 2014 Results of an analysis that investigated the effects of obesity of treatment outcomes presented at the 2014 Genitourinary Cancers Symposium.
    • 05 Jun 2013 Primary endpoint 'Overall-survival' has not been met.
    • 04 Jun 2013 Results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top